January 13, 2022
MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Ono Pharmaceutical’s archrival Opdivo (nivolumab) delivered nearly the same revenue on an NHI price basis in 2021, grabbing the top two slots in last year’s drug sales ranking in Japan, according to a tally...read more